Recent Advances and Future Trends of[18F]-Labeled PET Agents for Renal Imaging.

Abstract

Recent years have seen substantial advancements in renal positron emission tomography (PET) imaging. Targets for PET imaging include, but are not limited to, angiotensin receptors, norepinephrine transporters, and sodium-glucose cotransporters. All of those novel radiotracers inherit advantages of F18 radiochemistry, thereby allowing for higher clinical throughput or potentially increased diagnostic accuracy. The potential of such novel F18-labeled agents to yield imaging biomarkers, and their potential role for future renal molecular imaging, will be presented in the following article.